| US 7,585,667 B2 | ||
| Negative strand RNA virus replicon | ||
| Paul D. Olivo, St. Louis, Mo. (US); Peter L. Collins, Kensington, Md. (US); and Mark E. Peeples, Bexley, Ohio (US) | ||
| Assigned to The United States of America as represented by The Department of Health and Human Services, Washington, D.C. (US); and Rush University Medical Center, Chicago, Ill. (US) | ||
| Appl. No. 10/560,655 PCT Filed Jun. 14, 2004, PCT No. PCT/US2004/018783 § 371(c)(1), (2), (4) Date Aug. 11, 2006, PCT Pub. No. WO2005/005645, PCT Pub. Date Jan. 20, 2005. |
||
| Claims priority of provisional application 60/478521, filed on Jun. 13, 2003. | ||
| Prior Publication US 2006/0275774 A1, Dec. 07, 2006 | ||
| This patent is subject to a terminal disclaimer. | ||
| Int. Cl. C12N 15/86 (2006.01); C12N 7/01 (2006.01); C12N 15/45 (2006.01) | ||
| U.S. Cl. 435—320.1 [435/235.1; 435/325; 536/23.72] | 18 Claims |
| 1. A synthetic negative-strand respiratory syncytial virus (RSV) replicon comprising
a) a nucleotide sequence of said respiratory syncytial virus, wherein the sequences encoding the F, G and SH glycoproteins
are inactivated or deleted; and
b) a nucleotide sequence encoding a selectable marker suitable for selection, wherein said sequence encoding a selectable
marker is under the control of the respiratory syncytial virus replication machinery, wherein the replicon can be used to
biologically select cells containing stable, replicating, replicons, and wherein said replicon is non-cytotoxic to said cells
when said cells do not express F, G, and SH viral glycoproteins.
|